MetaCap

Cerus (CERS) vs Embecta (EMBC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cerus (CERS) has outperformed Embecta (EMBC) over the past year, gaining 14.2% versus a loss of 58.7%. Cerus is the larger company by market cap ($373.6 million vs $341.1 million), about 1.1 times the size. On valuation, Embecta trades at a lower forward P/E (3.4x vs 123.3x for Cerus).

Embecta pays a dividend yielding 7.64%, while Cerus does not currently pay one. Embecta converts more of its revenue into profit, with a net margin of 8.8% versus -6.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CERS+14.20%EMBC-58.68%
+112%+11%-89%
Nov 21, 20251 yearNov 20, 2026
CERS-65.74%EMBC-86.00%
+12%-43%-98%
Mar 21, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CERS versus EMBC key metrics
MetricCERSEMBC
Share price$1.85$6.02
Market cap$373.62M$341.09M
1-day change-2.63%-2.75%
YTD return-10.19%-49.33%
1-year return+14.20%-58.68%
5-year return-73.50%—
P/E ratio (TTM)—4.10
Forward P/E123.333.42
EPS (TTM)$-0.04$1.47
Dividend yield0.00%7.64%
Annual dividend$0.00$0.46
Revenue (latest FY)$233.80M$1.08B
Revenue growth (YoY)+16.13%-3.80%
Net income (latest FY)$-15.63M$95.40M
Gross margin—62.64%
Operating margin-3.71%22.41%
Net margin-6.68%8.83%
52-week high$3.47$14.78
52-week low$1.59$2.77
Distance from 52-week high-46.69%-59.27%
Analyst consensusstrong_buynone
Avg. price target upside+177.30%-33.55%
Average volume2.12M1.01M
Shares outstanding201.95M56.66M
Employees2611,850
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CERS has outperformed EMBC by 72.9 percentage points over the past year.
  • Embecta offers a meaningfully higher dividend yield (7.64% vs 0.00%).
  • Embecta is more profitable, keeping 8.8 cents of every revenue dollar as net income versus -6.7 cents for Cerus.
  • Cerus grew revenue faster in its latest fiscal year (+16.13% vs -3.80%).

About Cerus

CERS stock →

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Health Care · Medical/Dental Instruments · 261 employees

About Embecta

EMBC stock →

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.

Health Care · Medical/Dental Instruments · 1,850 employees

CERS vs EMBC FAQ

Which is bigger, Cerus or Embecta?

Cerus (CERS) is larger, with a market capitalization of $373.62M compared with $341.09M for Embecta (EMBC).

Which stock has performed better over the past year, CERS or EMBC?

CERS returned +14.20% over the past 12 months, compared with -58.68% for EMBC (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Cerus or Embecta?

Embecta pays a dividend yielding 7.64%, while Cerus does not currently pay a regular dividend.

Are Cerus and Embecta in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons